Citation for the published version:


Document Version: Accepted Version

Link to the final published version available at the publisher:

https://doi.org/10.1093/ijnp/pyz007

This article has been accepted for publication in the International Journal of Neuropsychopharmacology. © The Author(s) 2019. Published by Oxford University Press on behalf of CINP.

General rights
Copyright© and Moral Rights for the publications made accessible on this site are retained by the individual authors and/or other copyright owners.

Please check the manuscript for details of any other licences that may have been applied and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. You may not engage in further distribution of the material for any profitmaking activities or any commercial gain. You may freely distribute both the url (http://uhra.herts.ac.uk/) and the content of this paper for research or private study, educational, or not-for-profit purposes without prior permission or charge.

Take down policy
If you believe that this document breaches copyright please contact us providing details, any such items will be temporarily removed from the repository pending investigation.

Enquiries
Please contact University of Hertfordshire Research & Scholarly Communications for any enquiries at rsc@herts.ac.uk
An insight into Z-drugs abuse and dependence: an examination of reports to the European Medicines Agency (EMA) database of suspected Adverse Drug Reactions (ADR).

Regular research article

Fabrizio Schifano MD, FRCPsych; Stefania Chiappini* MD; John M. Corkery, BA Hons (Open), MSc; and Amira Guirguis, PhD, MPharm.

Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hertfordshire AL10 9AB, UK.

*Corresponding author:

STEFANIA CHIAPPINI
stefaniachiappini9@gmail.com
0039 333 1698033

Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit
School of Life and Medical Sciences
University of Hertfordshire
Hertfordshire AL10 9AB, UK

© The Author(s) 2019. Published by Oxford University Press on behalf of CINP.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Abstract

Background: Although originally marketed as safe alternatives to the habit-forming benzodiazepines, growing numbers of zaleplon, zolpidem, and zopiclone (‘Z-drugs’) clinical concerns relating to their potential of abuse, dependence and withdrawal have been reported overtime. We aimed here at assessing these issues analysing datasets of Adverse Drug Reactions (ADR) provided by the European Medicines Agency (EMA) through the EudraVigilance (EV) system.

Methods: Analysing the ADR databases of each Z-drug, descriptive analyses have been performed on cases, and Proportional Reporting Ratios (PRRs) computed.

Results: An overall number of 33,240 (e.g. 23,420 zolpidem; 9,283 zopiclone; and 537 zaleplon) misuse/abuse/dependence/withdrawal-related ADRs, corresponding to some 6,246 unique patients given Z-drugs, were here identified. Cases were studied and described, including demographic characteristics and clinical data, such as concomitant drugs, doses, routes of administration, and outcomes of the reactions, being fatalities recorded. Considering PRR values, and in comparison with zopiclone, zolpidem was more frequently involved in both misuse/abuse and withdrawal issues. Zolpidem and zopiclone presented with the same dependence risk, but zopiclone was the most involved in overdose ADRs. If compared with zaleplon, zopiclone presented higher
dependence and overdose-related issues, but slightly lower misuse/abuse and withdrawal PRR values.

Conclusion: Current data may only represent a gross underestimate of the Z-drugs’ misusing issues’ real prevalence. Caution should be exercised when prescribing those molecules, especially for patients with psychiatric illnesses and/or history of drug abuse. We recommend the need to invest in proactive pharmacovigilance activities to better and promptly detect, understand and prevent any possible misusing potential of prescribed medications.

Keywords: adverse drug reactions; Z-drugs; zolpidem; zaleplon; zopiclone; EMA.

Significance Statement

Although originally marketed as safe alternatives to the habit-forming benzodiazepines, growing concerns about zaleplon, zolpidem, and zopiclone (‘Z-drugs’) abuse, dependence and withdrawal issues have been reported over the last decade. The analysis of Z-drugs’ related misuse/abuse/dependence/withdrawal cases collected by the European Medicines Agency (EMA) EudraVigilance (EV) database here provided firm, and large scale, evidence that Z-drugs may be abused for recreational purposes. Physicians should prescribe Z-drugs with caution, especially to vulnerable clients.
**Introduction**

Although sharing with benzodiazepines a similar mechanism of action, the non-benzodiazepine hypnotics zaleplon, zolpidem, and zopiclone (‘Z-drugs’) appeared on the market as safe substitutes for benzodiazepines, purportedly having both a reduced abuse potential and propensity to tolerance and withdrawal due to improved pharmacokinetics (Gunja N, 2013). Despite such expectations, large levels of cases of misuse, abuse, dependence and death involving Z-drugs have been reported over the last decade or so (Atkin et al., 2018).

**Clinical pharmacological issues**

Z-drugs are GABA-A receptor modulators chemically unrelated to benzodiazepines approved for the short-term management of insomnia disorders (NICE, 2004) due to their hypnotic effects by reducing sleep latency and improving sleep quality (Nutt and Stahl, 2010). Like benzodiazepines, Z-drugs are agonists of the GABA receptor complex and therefore enhancing GABA-mediated neuronal inhibition. However, their binding selectivity and pharmacokinetic profiles have been reported to minimise the possibility of side-effects similar to those produced by benzodiazepines, e.g. next day sedation, dependence and withdrawal (NICE, 2004).

Among Z-drugs, zopiclone was the first compound developed, binding with high affinity and functional potency the benzodiazepine receptor complex. With an
absorption time of about 2 hours and an elimination half-life of 4-5 hours, its clinical use is in the 3.75–7.5 mg dosage range (EMC. Zopiclone, 2017). Zolpidem is an imidazopyridine with an oral bioavailability of 70% and an elimination half-life of 2.5 hours (NICE, 2004; Nutt and Stahl, 2010). It is normally indicated at 10mg dosages (Victorri-Vigneau et al., 2007). Zaleplon is a rapidly absorbed pyrazolopyrimidine, with an elimination half-life of 1 hour (NICE, 2004). Zaleplon use, at 5–20 mg dosage, is currently indicated only for use in patients with initial insomnia, and an extended-release formulation is in development (Ebert et al., 2006). Z-drugs treatment should usually vary from a few days to 2 weeks with a maximum of 4 weeks, including tapering-off where appropriate.

**Misuse, abuse, dependence and withdrawal issues**

Despite the reported lack of tolerance and dependence (Lader, 1992; Voderholzer et al., 2001; Zammit G, 2009), the occurrence of both rebound insomnia (Lader, 1992; Ebert et al., 2006) and withdrawal symptoms after a therapeutic dosage abrupt discontinuation of Z-drugs has been described, and especially so in alcohol-dependent and drug abusing patients (Ayorinde and Sampson, 1998; Hajak G, 1999; Hajak et al., 2003; Johansson et al., 2003; Ebert et al., 2006; Zammit G, 2009; Morinan and Keaney, 2010). Furthermore, a range of case series and post-marketing surveillance studies have given rise to growing levels of clinical concerns among clinicians (Victorri-Vigneau et al., 2007).
suggesting that the prevalence of Z-drugs’ misusing issues could have been underestimated compared with benzodiazepines (Zammit, 2009). Z-drugs’ withdrawal symptoms, typically associated with the abrupt cessation of long-term, high dosage intake may include: insomnia, anxiety, euphoria irritability, tremor, inner restlessness, speech difficulties, abdominal pain, hypertension, tonic-clonic seizures, and confusion/disorientation/delirium (Aranko et al., 1991; Wong et al., 2005; Flynn and Cox, 2006). The use of either idiosyncratic routes of administration (e.g. injecting) or the intake of high dosages, may well increase the risk of Z-drugs’ abuse (Victorri-Vigneau et al., 2007). Drug misusers may be attracted by Z-drugs because they are not typically monitored during drug treatment programmes (Sikdar and Ruben, 1996; Rooney and O’Connor, 1998; Gunja, 2013; Ott et al., 2017; Schifano et al., 2018).

Z-drugs current regulation; near misses; and fatalities

According to the World Health Organization (WHO) the occurrence of zolpidem abuse and dependence would be similar to that of benzodiazepines and, different from zopiclone and zaleplon, in 2001 this molecule was placed in the same schedule of benzodiazepines (UNODC, 2001). Conversely, in 2013 the UK’s Advisory Council on the Misuse of Drugs (ACMD) concluded that zaleplon and zopiclone should be controlled in the same manner as zolpidem. Overall, zaleplon tends to be reported as the least misused, while zopiclone and zolpidem are both identified as the most misused
(ACMD, 2013).

To assess the Z-drugs’ misuse/abuse/dependence and withdrawal-related issues, our study aimed at analysing the related EMA EudraVigilance (EV) databases, collecting the voluntary reports of suspected ADRs for all medicinal products authorized in the European Economic Area/EEA.

**Methods**

The European pharmacovigilance system and its functions of detection, assessment, understanding, and prevention of adverse drug reactions (ADRs) or any other drug-related problem have been improved in parallel with the 2012 pharmacovigilance legislation (EMA EV 2016; Sessa et al., 2018). The European Medicines Agency (EMA) is responsible for the safety monitoring of medicines operating through EudraVigilance (EV), a system managing and analysing information on suspected ADRs to medicines which have been authorised in the European Economic Area (EEA) (EMA EV, 2016), although reports are received non-EEA countries as well (for a better understanding of the EMA organization of data collection, please refer to the paper supplementary material).

In order to assess the Z-drugs’ misusing issues, a formal request was sent to EMA for all abuse/misuse/dependence/withdrawal Z-drug-related data. The Individual Case Safety
Reports (ICSR) were identified considering the Preferred Terms (PTs) mentioned. The request included the following PTs: ‘drug abuse’, ‘intentional product misuse’, ‘drug dependence’ and ‘withdrawal syndrome’ or all the PTs terms included in the broad Standardised MedDRA Queries (SMQ) ‘Drug abuse, dependence and withdrawal’ (MedDRA, 2010). The level 2A EV frequency table and line listing of the requested ADRs were here retrieved. Level 2A access meant that cases were provided with general information (e.g. sender, type of report, reporter qualification), some anonymised patient information, reaction (event) information with its outcome, and drug-related information (e.g. start date, duration, dose, pharmacological form, route of administration) (see also EMA, 2018). In the EV database each individual patient had a code (EV local number) for unequivocal identification. ADRs’ numbers differed from those referring to single patients, since different reporters/senders could have independently flagged the same ADR to EMA. Conversely, several ADRs (involving various organ classes, hence identified with specific PTs) relating to the searched ADR (e.g. abuse/misuse/dependence and withdrawal) could have been reported as well for the same patient (HMA EMA, 2017). The zolpidem, zopiclone, and zaleplon data analysis referred to a range of parameters, including: socio-demographic characteristics (age and sex); source/reporter country (EEA or non-EEA) and reporter qualification (i.e. pharmacist, physician); ADR outcome (fatal, recovered, resolved); drug dosages; and possible concomitant drug(s). The analysis included cases of abuse/misuse/dependence
and withdrawal ADRs, focusing on fatalities as well. Suicides were here reported as ‘suicide attempt’, ‘suicidal behaviour’ and ‘intentional self-injury’; conversely, ‘suicidal ideation’, and ‘overdose’ (including intentional) were not included (MedDRA, 2010). The ADRs considered here were, per se, voluntary and unsolicited communications reported by both Regulatory Authorities of the EU Member States where the reaction occurred, and/or by the Marketing Authorisation Holders for those ADRs occurring outside the EEA. Within the SMQs ‘drug abuse, dependence and withdrawal’ section the following adverse reactions were identified: dependence, drug abuser, drug diversion, drug use disorder, drug withdrawal convulsions, drug withdrawal headache, drug withdrawal syndrome, intentional overdose, intentional product misuse, intentional product use issue, overdose, prescription drug use without prescription, product use in unapproved indication, product use issue, substance use disorder, substance abuser, and withdrawal syndrome. ‘Misuse’ was here meant to be the ‘intentional use for a therapeutic purpose by a patient or consumer of a product, over-the-counter or prescription, other than as prescribed or not in accordance with the authorised product information’. Conversely, ‘abuse’ was defined here as the ‘intentional, non-therapeutic use by a patient or consumer of a product, over-the-counter or prescription, for a perceived reward or desired non-therapeutic effect including, but not limited to, getting high (euphoria)’. The term ‘addiction’, typically replaced by ‘dependence’, is the ‘overwhelming desire by a patient or consumer to take a drug for non-therapeutic
purposes together with inability to control or stop its use despite harmful consequences’. Finally, ‘withdrawal’ referred here to: ‘a substance-specific syndrome which follows cessation or reduction in the intake of a psychoactive substance previously regularly used’ (MedDRA, 2010). Those ADRs which were listed as ‘suspect drug’, meaning that the reporter suspected this drug, and not the concomitant medicine(s), to have caused the index ADR (EMA EV, 2016) were here included.

The Proportional Reporting Ratio (PRR) approach, defined as: ‘the ratio between the frequency with which a specific adverse event is reported for the drug of interest (relative to all adverse events reported for the drug) and the frequency with which the same adverse event is reported for the drug(s) in the comparison group (relative to all adverse events for drugs in the comparison group)’, was here considered (EMA EV-Ewg, 2006). A PRR greater than 1 suggests that the adverse event is more commonly reported for individuals taking the drug of interest relative to the comparison drug(s), while if the PRR value is less than 1, there is a disproportion of reporting in the sense that the specific event is less frequently reported in association with the suspect drug than with the others. The PRR confidence intervals were here computed as well, indicating with PRR- and PRR+ respectively the lower and upper bounds of the 95% confidence interval (EMA EV-Ewg, 2006; for a better understanding of the PRR calculation, please refer to the paper supplementary material).

Ethics
Because of EMA protection of privacy and integrity of individuals, data relating to patients affected were fully and completely de-identified/anonymised; therefore, it was not possible at all to derive from such data the names of the individuals affected by the ADR, not even their country or town. Hence, per definition, the need to obtain their informed consent was here not applicable. Moreover, certain data elements (e.g. names/identifiers of individuals involved; country-specific information, nationally authorized products etc) were not disclosed (EMA, 2016).

The study has been ethically approved by the University of Hertfordshire Ethics' Committee, with reference number LMS/PGR/UH/03234 (March 5th, 2018).

Results
Zaleplon ADRs
Overall, the number of the EMA 2003-2017 zaleplon ADRs collected by was 4,270 (Table 1). Out of the total number of ADRs, those relating to misuse-abuse-dependence-withdrawal issues and judged by the reporter as ‘suspect’ were 537 (12.58%), with ‘intentional overdose’ being the most represented (51.9%). Most ADRs were reported by physicians from non-EEA countries (53.2%), whilst pharmaceutical companies were the most typical (58.6%) reporting agencies. Typically, these ADRs involved adult (18-64 years old) females. A lone Z-drug ingestion was reported in 33/112 (29.4%) of
zaleplon, whilst a concomitant use of prescribing drugs mostly involved antidepressants (19.8%), benzodiazepines (17.8%), and ethanol/other Z-drugs (13.9%) has been described. A nasal atypical intake modality was reported in 7 zaleplon cases. No information of dosage was here provided.

Finally, a range of suicide-related (‘suicide attempt’ and ‘suicidal ideation’) ADRs were reported (respectively 13.6% and 5.21%).

Zolpidem ADRs

Out of the total number of zolpidem ADRs (206,315), those relating to misuse-abuse-dependence-withdrawal issues and judged by the reporter as ‘suspect’ were 23,420 (11.35%) (Table 1). Most ADRs were reported by physicians from non-EEA countries (49.7%), pharmaceutical companies having been the most typical (41.3%) reporting agencies. ‘Drug use disorder’ (40.0%), ‘overdose’ (23.7%), and ‘intentional overdose’ (16.7%) were the most represented ADRs. Typically, these ADRs involved adult (18-64 years old) females. A lone Z-drug ingestion was reported in 1,856/4,374 (42.4%) zolpidem cases, whilst a concomitant use of prescribing drugs was reported, mostly involving antidepressants (26.6%); benzodiazepines (19.0%); and opiates/opioids (14.2%). Moreover, a range of recreational drugs were identified, specifically: alcohol (174 cases); cocaine (30 cases); amphetamines (21 cases); and cannabis (13 cases). Atypical intravenous (22 cases); nasal (5 cases); and sublingual (1 case) intake
modalities were here reported for zolpidem. Dosages were higher than 20mg in 7,371 ADRs; in 6,234 of these cases, the dosage was above 100mg; and in 20 ADRs (7 cases) it was in excess of 2,000mg. Finally, a range of suicidal behaviour-related ADRs were reported for zolpidem, including: ‘intentional self-injury’ (102/23,420: 0.5%); ‘suicidal behaviour’ (44/23,420: 0.2%); and ‘suicide attempt’ (3,101/23,420: 13.2%). The rates of ADRs with a fatal outcome were higher for zolpidem (20.3%) in comparison with both zopiclone (9.33%) and zaleplon (1.1%).

**Zopiclone ADRs**

As for zaleplon and zolpidem, most zopiclone-related ADRs were reported by physicians from non-EEA countries (45.8%), with pharmaceutical companies having been the most typical (51.4%) reporting agencies. Out of the total number of ADRs (65,140), those relating to misuse-abuse-dependence-withdrawal issues and judged by the reporter as ‘suspect’ were 9,283 (14.25%) (Table 1), with the most represented ADRs including: ‘intentional overdose’ (29.9%); ‘overdose’ (23.1%); and ‘drug use disorder’ (23.1%). Typically, these ADRs involved adult (18-64 years old) females. Alone zopiclone ingestion was reported in 416/1,760 (23.6%) cases; as for zaleplon and zolpidem, a concomitant use of prescribing drugs was reported, mostly involving: benzodiazepines in 891/4,374 (20.4%) cases; antidepressants in 658/4,374 (15.0%) cases; antipsychotics in 475/4,374 (10.9%) cases; and opiates/opioids in 131/4,374

Downloaded from https://academic.oup.com/ijnp/advance-article-abstract/doi/10.1093/ijnp/pyz007/5306970 by :: user on 07 February 2019
cases (2.99%). Moreover, a range of recreational drugs were identified (e.g. cannabis in 12 cases; cocaine in 6 cases; methamphetamines in 1 case); and intravenous and subcutaneous intake modalities were reported as well. Finally, as for zolpidem, a range of suicidal behaviour-related ADRs were reported, including: ‘intentional self-injury’ (111/9,283: 1.2%); ‘suicidal behaviour’ (43/9,283: 0.5%); and ‘suicide attempt’ (2,526/9,283: 27.2%). When dosages were reported, levels in excess of 15mg were described in 577 (360 individuals) of zopiclone cases, including 205 ADRs (120 cases) where the dosage ingested was in the 450-2,250mg range.

**Analysis of the PRR values**

Considering the PRR values (Tables 2 and 3), in comparison with zopiclone, zolpidem was more involved in both misuse/abuse and withdrawal issues, whilst zopiclone was more involved in overdose ADRs. Conversely, zolpidem and zopiclone presented with the same dependence risk. If compared with zaleplon, zopiclone and zolpidem presented higher dependence and withdrawal, but slightly lower misuse/abuse and withdrawal, PRR values. Lower and upper bounds of the PRR confidence interval are reported in Table 3.

**Discussion**
To the best of our understanding, this paper is the first to provide uniquely systematic data in terms of identification and analysis of zolpidem; zopiclone; and zaleplon misuse/abuse/dependence and withdrawal issues. Present data were extracted from a high-quality, large-scale, pharmacovigilance database such as the EMA’s EV. Together with the World Health Organization’s Drug Monitoring Program, the EV database is considered a worldwide reference standard (Schifano and Chiappini, 2018). Most literature papers, so far, were based on small case series/single case studies (Aranko et al., 1991; Sikdar and Ruben, 1996; Rooney and O’Connor, 1998; Wong et al., 2005; Flynn and Cox, 2006; Chiaro et al., 2018). Conversely, current findings referred to overall much larger (e.g. 33,240 ADRs; corresponding to some 6,246 unique cases) numbers of patients presenting with Z-drugs’ misusing issues. Indeed, current data may only represent a gross under estimate of the Z-drugs’ misusing issues’ real prevalence. In fact, reports were here submitted spontaneously, and levels of misperception that these drugs are safe, which could prevent professionals from reporting, may still be identified (Medsafe, 1998). The analyses of the EV databases confirmed the diversion potential and the possibility of abuse/misuse/dependence and withdrawal issues related to all Z-drugs (zaleplon, zopiclone, and zolpidem), albeit some differences have emerged within this group. In comparison with zaleplon the misuse/abuse issues seemed here to be lower for zopiclone and zolpidem. Conversely, if compared with zopiclone, zolpidem emerged as being more frequently related to misuse/abuse; and withdrawal
reports; if compared with zaleplon, zolpidem was more frequently related to dependence; and overdose reports. Among Z-drugs, zolpidem was the most frequently reported in the EV dataset, being associated with intravenous administration; very high dosage consumption; and concomitant use of recreational drugs. These data are consistent with previous suggestions (Griffiths and Johnson, 2005; Rousselet et al., 2017) and recent reports based on both zolpidem-related falsified prescriptions’ rates in France (Jouanjus et al., 2018) and clinical dependence issues’ data from an Indian tertiary care centre (Shukla et al., 2016). Overall, zaleplon ADRs were: numerically lower than zopiclone- and zolpidem-related ADRs; and less frequently associated with both idiosyncratic/atypical ways of administration and concomitant recreational drug intake. Hence, one could tentatively identify in zaleplon the relatively (Desousa, 2009; Paparrigopulos et al., 2009) ‘most safe’ Z-drug, A full comparison among Z-drugs’ should however consider as well the precise worldwide prescription figures, which could serve as a proper denominator. Indeed, within the Z-drug group, one could argue that zaleplon may present with the lowest availability levels due to its higher purchase costs (NICE, 2004). Regarding zopiclone use, Jaffe et al (2004) assessed its use among 297 drug addicts who had been consecutively admitted to addiction treatment centres in the United Kingdom (UK). It emerged that more than half had used zopiclone, which ranked fourth after diazepam, temazepam and nitrazepam. About 80% of zopiclone users had obtained the drug through a prescription, but 42% reported having purchased
it on the streets (Jaffe et al., 2004). Analysing the misuse patterns of benzodiazepines and Z-drugs’ users, Kapil et al. reported that 29.6% had ever misused them, with 40.5% of individuals misusing at least two of these medications. Diazepam (53.4%) and zopiclone (24.1%) were the most frequently reported medications, with decreasing numbers of individuals misusing lorazepam (22.4%), alprazolam (17.2%), zaleplon (11.2%), nitrazepam (10.3%), phenazepam (7.8%) and zolpidem (5.2%). Moreover, using data from a Health Insurance reimbursement database, which collects information of 77% of the French population, Ponté et al. (2018) assessed the extent and risk of abuse of opioid analgesics related to benzodiazepines and hypnotics; they considered both the molecules’ Doctor Shopping Quantity/DSQ (intended to assess the extent of abuse) and the Doctor Shopping Index/DSI (intended to identify a signal of abuse). Interestingly, they found that the DSQ of anxiolytics and hypnotics (influenced by their large availability levels) was 10 times higher than that of opioids. Conversely, the DSI of opioids (2.79%) was higher than the one of both hypnotics (2.06%) and anxiolytics (1.81%). Among benzodiazepines, flunitrazepam and zolpidem presented with the highest DSI values (13.2% and 2.2% respectively) (Ponté et al., 2018). Overall, higher levels of physical and compulsive signs of dependence with zolpidem, rather than with zopiclone (Griffiths and Johnson, 2005; Rousselet et al., 2017; Ponté et al., 2018), have been described.
Current Z-drugs’ data are consistent with the new trends in prescribing drugs’ misuse (Throckmorton et al., 2018), which is at times occurring within the context of the rising levels of Novel Psychoactive Substances (NPS) misuse (Schifano et al., 2018). It is however a reason of concern that a range of further, prescribing and recreational, psychotropics were here identified in combination with Z-drugs, including: antidepressants, benzodiazepines, antipsychotics, other Z-drugs, opiates/opioids, alcohol, cannabis, cocaine, methamphetamine, and ketamine. Present data may support previous hypotheses, e.g. that there may two sub-sets of individuals misusing with Z-drugs; the first group may include patients with psychiatric comorbidities (Zammit G, 2009; Lin et al., 2017), who were originally started with these molecules for insomnia but who developed tolerance and withdrawal phenomena, requiring increasing dosages overtime (Griffiths and Johnson, 2005); and the second population may include young people, who are ingesting large Z-drug dosages in combination with other recreational compounds and through idiosyncratic intake modalities (Sikdar and Ruben, 1996; Ayorinde and Sampson, 1998; Rooney and O’Connor, 1998; Hajak G, 1999; Johansson et al., 2003), which can increase the drug bioavailability levels (Victorri-Vigneau et al., 2007) and hence facilitate achieving better euphoria.

Fatalities were here reported for all Z-drugs, although this typically occurred mostly with zolpidem, and zopiclone, both typically ingested in a poly-drug misuse scenario, thus confirming previous reports(Garnier et al., 1994; Casula et al., 2013; Gunja, 2013).
The comparatively low levels of zaleplon toxicity/fatalities here identified could however be associated with the molecule ultra-short half-life and rapid ante-mortem metabolism, which can affect its detection (Gunja, 2013). Mortality from Z-drugs may be similar to that of benzodiazepines (Garnier et al., 1994; Reith et al., 2003). A UK study on zopiclone-related deaths (Buckley and McManus, 2004) found that the zopiclone fatal toxicity index was similar to that of zolpidem but lower if compared with flurazepam, flunitrazepam, temazepam, triazolam, and nitrazepam. It is of interest to note that a number of suicidal behaviour-related ADRs (e.g. suicide attempts; suicidal ideation) were here identified, and especially so for both zolpidem and zopiclone. This confirms previous findings, suggesting increasing levels of suicidal ideation, suicide attempts, and suicide risk in patients administered with Z-drugs (Brower et al., 2011; McCall et al., 2017).

Limitations

The number of any given compound-related ADRs may not reflect the full extent of the molecule’s potential of misuse. In fact, levels of reporting, which is voluntary in nature, are depending on the index molecule clinicians’ awareness of safety concerns; its market availability levels; and extent of use. Furthermore, a Z-drugs’ illicit market exists (Kapil et al., 2014), further complicating the computation of a reliable, Z-drugs’ availability levels, denominator. The ADRs’ reports presented here with missing data,
which often included both the dosages ingested and the background diagnosis. Based on the current reporting rules in the EEA, report duplications were here possible as well, i.e. the same ADR could be reported by different healthcare professionals. To mitigate this issue, however, the number of individual cases was here unequivocally identified through a code number. Finally, suspected ADRs do not conclusively prove causality between a specific drug and a given ADR; the ADR may be a symptom of another illness, it could be associated with another medical product taken by the patient at the same time or caused by their interaction.

**Conclusions**

In being perceived as more effective and tolerable hypnotics, the levels of Z-drugs’ availability has risen overtime, in parallel with a fall in benzodiazepine prescriptions (Siriwardena et al., 2006; ACMD, 2013). However, both previous number of anecdotal reports and current data may well suggest that the misuse/abuse/dependence and withdrawal issues may be associated with the use of all Z-drugs, although zaleplon may present with comparatively smaller levels of risk. Present data may further support the need of encouraging careful prescribing, in line with the UK government's initiative to review the evidence for dependence on, and withdrawal from, prescribed medicines (Pollman et al., 2015; Kuntz et al., 2017; Gov.uk, 2018). Special caution is here suggested in prescribing Z-drugs to vulnerable clients, e.g. inmates; those with
psychiatric comorbidities; and recreational drug misusers. To manage clinical Z-drugs’
dependence cases, the use of benzodiazepines (e.g. diazepam or clonazepam),
gabapentinoids, trazodone, and quetiapine has been suggested (Mariani and Levin,
2007; Pottie et al., 2018).
Voluntary reporting systems should be improved, with new tools/approaches to be
hopefully made available. To assess the abuse potential of centrally active drugs, a
range of both pre-marketing evaluation and proactive post-marketing surveillance
activities should be strongly encouraged. A proactive pharmacovigilance may help in
monitoring and anticipate changes in drug abuse, using elements of clinical,
epidemiological, basic science, and social science expertise in order to increase
clinicians’ awareness of drug safety issues (Throckmorton et al., 2018).

Funding
This research received no specific grant from any funding agency in the public,
commercial or not-for-profit sectors.

Acknowledgments
The authors acknowledge the support offered by the European Medicines Agency
(EMA) in providing access to the EudraVigilance (EV) database.
Conflict of interest

The Authors declare no conflicts of interest with respect to the content of this manuscript; however, F.S. is a member of the EMA Psychiatry Advisory Board.
References


European Medicines Agency (EMA). EudraVigilance (EV) (2016). Available at:
t_000679.jsp&mid=WC0b01ac05800250b5 (Accessed 13 July 2018).

European Medicines Agency (EMA) (2016). European Medicines Agency policy on
access to EudraVigilance data for medicinal products for human use.
EMA/759287/2009 Revision 3. Available at:
https://www.ema.europa.eu/documents/other/european-medicines-agency-policy-
10 October 2018).

Case Safety Report form. Version 1.1. Available at:

European Medicines Agency (EMA). Eudravigilance Expert Working Group (EV-Ewg)
(2006). Guideline on The Use Of Statistical Signal Detection Methods In The
Eudravigilance Data Analysis System. Available at:


Table 1: Number of EMA database Z-drugs’ (zaleplon, zopiclone, and zolpidem) misuse-/abuse-/dependence- and withdrawal-related ADRs (2003-2017).

<table>
<thead>
<tr>
<th></th>
<th>ZALEPLON</th>
<th>ZOPICLONE</th>
<th>ZOLPIDEM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total no. ADRs</td>
<td>4,270</td>
<td>65,140</td>
<td>206,315</td>
</tr>
<tr>
<td>Suspect abuse/misuse/dependence/withdrawal-related ADRs</td>
<td>537 (12.58%) (IC 95%: 11.60-13.61%)</td>
<td>9,283 (14.25%) (IC 95%: 13.98-14.52%)</td>
<td>23,420 (11.35%) (IC 95%: 11.21-11.49%)</td>
</tr>
<tr>
<td>No. of unique patients</td>
<td>112</td>
<td>1,760</td>
<td>4,374</td>
</tr>
<tr>
<td>Gender most typically represented</td>
<td>F (F/M ratio: 3.9)</td>
<td>F (F/M ratio: 1.09)</td>
<td>F (F/M ratio: 1.6)</td>
</tr>
<tr>
<td>Age range (years) most typically represented</td>
<td>18-64 (39%)</td>
<td>18-64 (68%)</td>
<td>18-64 (65.7%)</td>
</tr>
<tr>
<td>ADRs most typically represented</td>
<td>Intentional overdose (51.9%), overdose (14.1%), drug use disorder (11.4%)</td>
<td>Intentional overdose (29.9%), overdose (23.1%), drug use disorder (23.1%)</td>
<td>Drug use disorder (40.0%), overdose (23.7%), intentional overdose (16.7%)</td>
</tr>
<tr>
<td>Concomitant drugs most typically represented</td>
<td>Antidepressants in 20/101 (19.8%) cases, benzodiazepines in 18/101 (17.8%) cases, ethanol/other Z drugs in 14/101 (13.9%) cases</td>
<td>Benzodiazepines in 891/4,374 (20.4%) cases, antidepressants in 658/4,374 (15.0%) cases, antipsychotics in 475/4,374 (10.9%) cases</td>
<td>Antidepressants in 468/1,760 (26.6%) cases, benzodiazepines in 334/1,760 (19.0%) cases, opiates/opioids in 250/1,760 (14.2%) cases</td>
</tr>
</tbody>
</table>
Table 2: Z-drugs (zaleplon, zolpidem and zopiclone) misuse-/abuse-/dependence/withdrawal- and overdose-related ADRs; PRR computation.

<table>
<thead>
<tr>
<th>Zaleplon ADRs</th>
<th>No of reactions ADRs</th>
<th>Proportion of Zaleplon ADRs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dependence (A11)</td>
<td>5</td>
<td>0.001</td>
</tr>
<tr>
<td>Withdrawal syndrome (A12) + Drug withdrawal syndrome (A13) + Drug withdrawal headache (A14) + Drug withdrawal (A15)</td>
<td>89</td>
<td>0.023</td>
</tr>
<tr>
<td>Intentional overdose (A16) + Overdose (A17)</td>
<td>76</td>
<td>0.019</td>
</tr>
<tr>
<td>Other Adverse Events (B)</td>
<td>3,733</td>
<td>0.868</td>
</tr>
<tr>
<td>Total</td>
<td>4,270</td>
<td>1.000</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Zopiclone ADRs</th>
<th>No of reactions ADRs</th>
<th>Proportion of Zopiclone ADRs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug abuser (C1) + Drug diversion (C2) + Drug use disorder (C3) + Intentional product use issue (C4) + Intentional product misuse (C5) + Prescription drug used without prescription (C6) + Product use in unapproved indication (C7) + Product use issue (C8) + Substance abuser (C9) + Substance use disorder (C10)</td>
<td>2,507</td>
<td>0.043</td>
</tr>
<tr>
<td>Dependence (C11)</td>
<td>138</td>
<td>0.002</td>
</tr>
<tr>
<td>Withdrawal syndrome (C12) + Drug withdrawal syndrome (C13) + Drug withdrawal headache (C14) + Drug withdrawal (C15)</td>
<td>718</td>
<td>0.013</td>
</tr>
<tr>
<td>Intentional overdose (C16) + Overdose (C17)</td>
<td>5,920</td>
<td>0.096</td>
</tr>
<tr>
<td>Other Adverse Events (D)</td>
<td>55,857</td>
<td>0.846</td>
</tr>
<tr>
<td>Total</td>
<td>65,140</td>
<td>1.000</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Zolpidem ADRs</th>
<th>No of reactions ADRs</th>
<th>Proportion of Zolpidem ADRs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug abuser (E1) + Drug diversion (E2) + Drug use disorder (E2) + Intentional product use issue (E4) + Intentional product misuse (E5) + Prescription drug used without prescription (E6) + Product use in unapproved indication (E7) + Product use issue (E8) + Substance abuser (E9) + Substance use disorder (E10)</td>
<td>9,744</td>
<td>0.050</td>
</tr>
<tr>
<td>Condition</td>
<td>Count</td>
<td>P-value</td>
</tr>
<tr>
<td>-----------</td>
<td>-------</td>
<td>---------</td>
</tr>
<tr>
<td>Dependence (E11)</td>
<td>423</td>
<td>0.002</td>
</tr>
<tr>
<td>Withdrawal syndrome (E12) + Drug withdrawal syndrome (E13) + Drug withdrawal headache (E14) + Drug withdrawal (E15)</td>
<td>2,433</td>
<td>0.018</td>
</tr>
<tr>
<td>Intentional overdose (E16) + Overdose (E17)</td>
<td>10,820</td>
<td>0.056</td>
</tr>
<tr>
<td>Other Adverse Events (F)</td>
<td>182,895</td>
<td>0.874</td>
</tr>
<tr>
<td>Total</td>
<td>206,315</td>
<td>1.000</td>
</tr>
</tbody>
</table>
Table 3: Z-drugs (zaleplon, zolpidem and zopiclone) PRR values

<table>
<thead>
<tr>
<th>ADRs</th>
<th>PRR Zolpidem vs Zaleplon (PRR- and PRR+)</th>
<th>PRR Zopiclone vs Zaleplon (PRR- and PRR+)</th>
<th>PRR Zolpidem vs Zopiclone (PRR- and PRR+)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Misuse/abuse</td>
<td>0.57 (0.55-0.59)</td>
<td>0.48 (0.43-0.53)</td>
<td>1.16 (1.11-1.21)</td>
</tr>
<tr>
<td>Dependence</td>
<td>2.00 (0.82-4.8)</td>
<td>2.00 (0.81-4.80)</td>
<td>1.00</td>
</tr>
<tr>
<td>Withdrawal</td>
<td>0.79 (0.76-0.81)</td>
<td>0.56 (0.29-1.06)</td>
<td>1.38 (1.27-1.49)</td>
</tr>
<tr>
<td>Overdose</td>
<td>2.90 (2.31-3.60)</td>
<td>5.00 (4.00-6.2)</td>
<td>0.58 (0.56-0.60)</td>
</tr>
</tbody>
</table>